Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement With Bristol-Myers Squibb Company (BMY)
5/9/2013 10:02:30 AM
More...
|
Adaptive Biotechnologies Launches Clonoseq, a More Sensitive, Accurate Assay to Detect Minimal Residual Disease (MRD) in Blood-Based Cancers.
12/7/2012 8:09:28 AM
More...
|
New Study Shows Adaptive Biotechnologies ImmunoSEQ Assay Significantly More Sensitive than Traditional Method to Detect Minimal Residual Disease in Leukemia
5/17/2012 10:14:24 AM
More...
|
Adaptive TCR Corporation Changes Name to Adaptive Biotechnologies
1/3/2012 11:01:40 AM
More...
|
Adaptive TCR Corporation Raises $5.8 Million in Series B Funding to Expand ImmunoSEQ Platform and Focus on Clinical Applications
6/10/2011 6:57:03 AM
More...
|
Adaptive TCR Corporation Launches the immunoSEQ(TM) Product Line - Visualizing the Immune System With Next-Generation Sequencing
10/21/2010 7:21:59 AM
More...
|
Adaptive TCR Corporation, a Fred Hutchinson Cancer Research Center Spinoff, Nabs $4.5M to Uncover Immune System Secrets
3/26/2010 8:34:39 AM
More...
|